Dr. Amiji gave an academic keynote presentation at Advancing Drug Development Forum on December, 12th 2024 in Cambridge, MA. This forum strives to attract and stimulate dialogue with key opinion leaders in biotech and pharma, executive leadership, senior directors, consultants, and a close network of CROs and CDMOs to further explore together novel solutions, promising technology breakthroughs and hearing how the entrepreneurial industry leaders are introducing and incorporating novel approaches in small molecule drug development, changing timelines and ROIs.

• Dr. Kanika Suri published a paper “Oral delivery of stabilized lipid nanoparticles for nucleic acid therapeutics” in Drug delivery and translational research. https://doi.org/10.1007/s13346-024-01709-4

In this research, we introduce an innovative Orally Delivered (OrD) LNP Platform, versatile in it’s capability of delivering both siRNA and mRNA. This work explores systematic formulation development that leads to stabilized OrD LNP in gastrointestinal media and shows strong effectiveness in gene knockdown and protein expression, paving the way for the creation of more accessible treatments for patients. This work promises to dawn of a new era of extra-hepatic LNP delivery!

• Dr. Valentina Di Francesco’s research was a finalist for the Best Basic Science Category at the 70th Annual Meeting of the American Rhinologic Society held on September 27-28, 2024, in Miami, FL.

• Dr. Amiji has been recognized in the updated August 2024 database of top-cited scientists, featured for career-long and recent-year contributions. This prestigious list, compiled from Scopus data, highlights the top 2% of researchers in their respective fields. 2024 Stanford University Annual Assessment of Author Citations

• The Research team participated in Northeastern University’s Pharm Sci Research Showcase 2024 held on September 13th, 2024.

• Dr. Amiji discusses on nasal spray as gamechangers. Read more about it here: New neffy nasal spray alternative to the EpiPen could be ‘a gamechanger’ for people with allergies

• Dr. Amiji presented and participated in the Ascendia Pharma’s Two-Day Technical Workshop on September 17th and 18th 2024, at the Crowne Plaza Hotel in Princeton, NJ

• Dr. Amiji was featured in the Medical Xpress article “Will the New COVID FLiRT Variant Lead to a Summer Surge? Watch for These Symptoms, Experts Say.” You can read more about it here: Will the New COVID FLiRT variant lead to a summer surge? Watch for these symptoms, experts say

• 15th July 2024 – Celebrated Paulo Faria’s last day in the lab. Wishing Paulo all the best in his future endeavors!

• May 2024 – Our long-time collaborator, Prof. Bruno Sarmento, visited our lab and Northeastern University.

• April 2024 – Post-doctoral fellows and graduate students presented posters at the NU 2024 RISE conference

• Dr. Amiji presented at American Association of Pharmaceutical Scientists (AAPS) webinar Lipid Nanoparticle-Based Endogenous Targeted Delivery of Nucleic Acid Therapeutics on MAY 9 2024

• AstraZeneca Admits Vaccine Can Cause Rare Blood-Clotting Condition Bouvé/ChE University Distinguished Professor Mansoor Amiji gives insight into the risk of getting thrombosis with thrombocytopenia syndrome, or TTS, if you received the AstraZeneca vaccine for COVID-19.

• Avoiding Safety Risks for mRNA Therapeutics Bouvé/ChE University Distinguished Professor Mansoor Amiji co-authored a paper in Nature Reviews Drug Discovery outlining several strategies to check for toxicity at the preclinical level of mRNA therapeutics to ensure patient safety.

• Bouvé’s Mansoor Amiji among three Northeastern professors recognized for extraordinary achievement in the field of medical and biological engineering

• Bouvé researchers awarded TIER 1 grants

• New Cancer Vaccines Could Provide Beneficial Alternative Therapy Bouvé/ChE University Distinguished Professor Mansoor Amiji sees the promise of new cancer vaccines amid encouraging results from treatment studies.

• 2023 Stanford University Annual Assessment of Author Citations

• Understanding the Efficacy of the COVID-19 Vaccine Bouve/ChE University Distinguished Professor Mansoor Amiji explains how the COVID-19 vaccine is designed to prevent severe illness, hospitalization, and death, rather than to eliminate infection entirely.

• New Treatments for Pancreatic Cancer Bouve/ChE University Distinguished Professor Mansoor Amiji is working with UC Davis and drug developer TargaGenix to create new treatments for pancreatic cancer.

• Everything to know about the common cold and how to treat symptoms “Our study is really focused on prevention, that initial exposure and how to enhance your defenses,” said lead author Mansoor Amiji, professor of pharmaceutical sciences at Northeastern University. (Featured in USA Today)

• 2022 Stanford University Annual Assessment of Author Citations

• Spring 2022 Spark Fund Awardees Bouve/ChE University Distinguished Professor Mansoor Amiji, ChE Assistant Professor Sara Hashmi, ECE Professor Purnima Ratilal-Makris, and MIE Assistant Professor Mohsen Moghaddam are recipients of the Spring 2022 Spark Fund Awards. The awards provide support to commercially valuable inventions (from any field) from university researchers in earlier stages of development. The goal of the award is to advance a technology or suite of technologies from academia towards commercialization.

Last updated: May 2025